Table 2.
Glucoregulation and lipid status at baseline and after eight weeks of UDCA or placebo treatment.
| Parameters | UDCA (n = 30) | Placebo (n = 30) | ||||
|---|---|---|---|---|---|---|
| Baseline (F0) | 8 weeks (F1) | 8 weeks—baseline (Δ) | Baseline (F0) | 8 weeks (F1) | 8 weeks—baseline (Δ) | |
| Glucoregulation | ||||||
| Glucose (mmol/L) | 9.1 ± 3.9 | 8.5 ± 2.7 | −0.6 ± 2.5 | 8.8 ± 3.0 | 9.0 ± 3.0 | 0.2 ± 1.5 |
| HbA1c (%) | 7.2 ± 1.8 | 7.0 ± 1.5 | −0.2 ± 0.6 | 7.3 ± 1.6 | 7.2 ± 1.6 | 0 ± 0.6 |
| Insulin (mIU) | 11.2 (6.5) | 11.1 (7.3) | -0.9 (5.2) | 10.7 (5.1) | 10.4 (5) | -0.3 (4.2) |
| HOMA IR | 3.9 (4.4) | 4.0 (2.9) | -0.4 (2) | 4.3 (4) | 4.4 (3.5) | -0.2 (1.3) |
| Lipids | ||||||
| Cholesterol (mmol/L) | 5.8 ± 1.4 | 5.3 ± 1.2 | −0.5 ± 1.5 | 5.1 ± 1.3 | 5.1 ± 1.1 | 0.0 ± 1.0 |
| Triglycerides (mmol/L) | 2.1 (2) | 1.9 (1.1) | -0.1 (1.2) | 1.8 (1.6) | 2.2 (1.7) | 0.1 (0.9) |
| HDL-C (mmol/L) | 1.2 ± 0.2 | 1.1 ± 0.2 | −0.1 ± 0.1 | 1.1 ± 0.2 | 1.1 ± 0.3 | −0.1 ± 0.2 |
| LDL-C (mmol/L) | 3.4 ± 1.2 | 3.2 ± 0.9 | −0.2 ± 1.3 | 2.8 ± 1.3 | 3.0 ± 1.0 | 0.2 ± 1 |
All values are expressed as mean ± SD or median (IQR). F0: beginning of study; F1: end of study; HbA1c: glycosylated hemoglobin A1c; HOMA IR: Homeostatic Model Assessment index; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol.